Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin , Gazi University Faculty of Dentistry , Turkey

Prof. Dr. Sibel Elif Gültekin is an accomplished academic and researcher in Oral Pathology and Periodontology at Gazi University, Ankara. With dual DDS and Ph.D. degrees, she has led the Department of Oral Pathology for a decade and significantly contributed to understanding oral cancer, odontogenic lesions, and HPV-related pathologies. Her collaborative research with institutions such as UCSF and the University of Cologne has yielded numerous high-impact publications and advancements in oral diagnostics. She has authored two books and published over 96 articles in reputable journals. A prominent figure in national and international research boards, Dr. Gültekin has also played a pioneering role in establishing oral pathology as a specialty in Türkiye. Her work integrates molecular biology with clinical oral health, emphasizing innovation, collaboration, and translational science. Recognized globally, she continues to mentor emerging scholars while contributing to policy-making and curriculum development in dental education.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Extensive Research Portfolio: Over 96 peer-reviewed publications, with 40 in SCI journals, reflects consistent scholarly productivity and scientific depth.

  • Citation Impact: High citation indices (Google Scholar: 1,381, h-index: 17) demonstrate strong academic influence and relevance in the field of molecular oral pathology.

  • International Collaborations: Long-term, productive collaborations with prestigious institutions including the University of Cologne and UCSF underline global recognition and trust.

  • Focused Expertise: Specialization in oral epithelial dysplasia, HPV-associated oral/oropharyngeal cancers, and molecular mechanisms of odontogenic lesions aligns closely with cutting-edge cell biology and translational research.

  • Academic Leadership: Established the Department of Oral Pathology in Türkiye and mentored future scientists, contributing to both academic infrastructure and talent development.

  • Editorial and Advisory Roles: Active roles in scientific boards and journals underscore her influence in shaping academic discourse and peer-review standards.

🛠 Areas for Improvement:

  • Patent Development: Incorporating translational research into patentable diagnostics or therapeutics would enhance practical impact and innovation scoring.

  • Funding & Industry Engagement: Broader engagement with industry-funded projects and clinical trials could further expand her work’s translational potential and outreach.

  • Global Clinical Guidelines Influence: Participation in international committees that develop clinical practice guidelines would strengthen policy-level impact.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin pursued her initial dental training and later earned dual Ph.D. degrees in Periodontology and Oral Pathology, demonstrating a unique interdisciplinary depth. She completed her undergraduate and doctoral education at Gazi University, Faculty of Dentistry, Ankara. Her academic journey also included prestigious international research fellowships at the University of Cologne (Germany) and the University of California, San Francisco (UCSF, USA), where she focused on advanced molecular mechanisms in oral diseases, especially HPV-related oncogenesis and tissue regeneration. Her training reflects a blend of clinical excellence and a strong foundation in molecular biology and translational research. Through a blend of local and global academic exposure, Dr. Gültekin has acquired cutting-edge knowledge and technical expertise, which she continues to leverage in her teaching and research. Her international education and academic credentials have contributed to building strong scientific bridges between Türkiye and the global dental research community.

🧪 Professional Experience:

Prof. Dr. Sibel Elif Gültekin has over 20 years of academic and research experience in dentistry, with a specialized focus on Oral Pathology and Periodontology. She currently serves as a full professor and head of the Oral Pathology Department at Gazi University Faculty of Dentistry, a position she has held for more than a decade. Dr. Gültekin has actively engaged in research collaborations with renowned institutions such as the University of Cologne and UCSF, significantly contributing to the fields of oral cancer and molecular diagnostics. She has completed over 50 research projects and advised numerous postgraduate theses. As a scientific advisor and board member for several national and international journals and associations, she plays a pivotal role in shaping academic and clinical standards. Her editorial appointments and leadership in symposia highlight her commitment to academic excellence and global research integration. She continues to lead innovation in oral health education and research policy.

🔬 Research Focus:

Dr. Gültekin’s research centers on the molecular pathology of oral diseases, with particular emphasis on oral epithelial dysplasia, HPV-induced oral/oropharyngeal cancers, and the genetic underpinnings of odontogenic tumors and cysts. Her studies have investigated biomarkers such as p16, PDCD4, and VIM3, enabling improved early detection and classification of oral malignancies. She is also involved in exploring microsatellite instability, loss of heterozygosity, and B-RAF/MEK inhibition in the context of oral and maxillofacial tumors. A major dimension of her work includes periodontal tissue regeneration and molecular mechanisms of tooth development, which bridges clinical periodontology with developmental biology. Her research is translational, aiming to bridge bench-to-chairside pathways, and supports the development of personalized diagnostic and therapeutic strategies. With over 1,300 citations and active involvement in global research initiatives, her investigations have significantly influenced current understanding and clinical approaches in oral pathology.

📄 Publications Top Notes:

  1. 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma – Genes, Chromosomes and Cancer (2024)

  2. 💊 Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review – Heliyon (2023)

  3. 🦷 Kişiselleştirilmiş Diş Hekimliği (Personalized Dentistry) – ADO Klinik Bilimler Dergisi (2023)

  4. 🧪 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer – ADO Klinik Bilimler Dergisi (2022)

  5. 🧫 PD-L1 Expression and CD8+ Lymphocyte Infiltration Predict Outcome in Oropharyngeal Squamous Cell Carcinoma – IJMS (2020)

🔍 Conclusion:

Prof. Dr. Sibel Elif Gültekin stands out as an exceptional and qualified candidate for the Best Researcher Award. Her work in the field of oral pathology and molecular diagnostics not only contributes to advancing science but also bridges basic research with clinical applications. With a solid foundation in interdisciplinary science, international collaboration, and academic leadership, she exemplifies the values the award seeks to honor. Her achievements strongly align with the criteria of sustained research excellence, innovation, and global impact.

Hatice Yesim Karasulu | Cellular Microenvironment Interactions | Excellence in Research

Posted on by sciencefather

Prof. Dr. Hatice Yesim Karasulu | Cellular Microenvironment Interactions | Excellence in Research

Prof. Dr. Hatice Yesim Karasulu , Ege University , Turkey

Prof. Dr. H. Yesim Karasulu is a distinguished academician in the field of pharmaceutical technology, currently serving as a Professor in the Department of Pharmaceutical Technology at Ege University, Faculty of Pharmacy, Turkey. She completed her Ph.D. at Ege University and advanced to Associate Professor in 2006 and Professor in 2011. Her work as a consultant at Ege University’s ARGEFAR since 2011 and her contributions to the Turkish Ministry of Health’s Pharmaceutical and Medical Devices Agency (2006–2024) underscore her significant impact on both academia and industry. She has collaborated on international research and development projects, and her achievements include patents and international grant-funded projects. Prof. Karasulu has published over 50 scientific papers and delivered numerous oral and poster presentations. Her expertise spans pharmaceutical formulations, drug delivery systems, and biopharmaceutics, positioning her as a leader in her field.

Publication Profile:

Google Scholar

Strengths for the Award:

Prof. Dr. H. Yeşim Karasulu is a highly accomplished and influential researcher in the field of pharmaceutical technology. With more than 50 publications, including articles in top journals and book chapters, she has demonstrated a deep commitment to advancing pharmaceutical research, particularly in the area of drug delivery systems. Her pioneering work on colloidal drug delivery systems such as liposomes, nano/microparticles, and SEDDS has had significant implications for drug development. Her collaboration with both academic institutions and the pharmaceutical industry, leading to patents and commercial products under pharmaceutical license, highlights the practical impact of her work. Additionally, her extensive involvement in research projects funded at national and international levels, as well as her leadership roles, showcases her ability to drive innovation and contribute to the scientific community.

Areas for Improvement:

While Prof. Dr. Karasulu has made remarkable contributions, continuing to build collaborative networks with global research institutions and fostering interdisciplinary research could help broaden the impact of her findings. Enhancing visibility in high-impact international conferences or fostering collaborations in underexplored regions might allow her work to reach new audiences, ensuring that her innovations in drug delivery systems are applied more widely across different health sectors.

Education:

Prof. Dr. H. Yesim Karasulu earned her Ph.D. in Pharmaceutical Technology from Ege University, Faculty of Pharmacy, where she also completed her undergraduate studies. Her academic journey includes post-doctoral research at the University of Vienna, Department of Pharmaceutical Technology and Biopharmaceutics, working under Prof. Dr. Franz Gabor. Prof. Karasulu’s comprehensive education laid a strong foundation for her pioneering research in the field of drug delivery systems. Her work has been recognized both nationally and internationally, as evidenced by her academic promotions and various prestigious grants. She has also contributed to the development of new pharmaceutical technologies, and her research has influenced both educational and professional practices in the pharmaceutical industry. Prof. Karasulu’s educational journey is marked by continuous development and contributions to advancing pharmaceutical sciences, which is reflected in her ongoing academic and consulting roles.

Experience:

Prof. Dr. H. Yesim Karasulu has a rich professional background in pharmaceutical sciences. After earning her Ph.D., she quickly advanced in academia, being promoted to Associate Professor in 2006 and Professor in 2011. Alongside her academic career, Prof. Karasulu has served as a consultant at Ege University’s ARGEFAR, contributing to the development of innovative drug delivery systems and pharmaceutical technologies. Her extensive experience in the pharmaceutical sector includes her role as a member of the Pharmaceutical Technology Commission at the Turkish Ministry of Health’s Pharmaceuticals and Medical Devices Agency from 2006 to 2024. Prof. Karasulu has also conducted post-doctoral research in Vienna, enhancing her expertise in drug delivery and biopharmaceutics. Her broad range of experiences has led to successful collaborations with both the academic and industrial sectors, resulting in patent applications and new pharmaceutical products, further highlighting her significant contributions to the field of pharmaceutical technology and drug delivery.

Research Focus:

Prof. Dr. H. Yesim Karasulu’s research focuses on the development, characterization, and evaluation of advanced drug delivery systems, particularly colloidal systems such as liposomes, nanoparticles, microemulsions, and self-emulsifying drug delivery systems (SEDDS). Her work aims to enhance the efficacy, stability, and bioavailability of pharmaceuticals, particularly through non-invasive routes like transdermal, nasal, and vaginal delivery. Prof. Karasulu is particularly interested in the physicochemical properties that govern drug absorption and permeation, conducting numerous studies on skin permeation, mucosal delivery, and targeted drug delivery to various organs. Her research is driven by a strong desire to bridge the gap between basic pharmaceutical technology and real-world clinical applications. She has contributed significantly to the scientific understanding of drug release mechanisms and the potential of microemulsions as novel carriers for active pharmaceutical ingredients. Prof. Karasulu’s work has been supported by numerous grants and has led to the development of several patents and ongoing product innovations in the pharmaceutical industry.

Publications Top Notes:

  1. Transdermal delivery of diclofenac sodium through rat skin from various formulations 📄💊
  2. Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations 🌿💉
  3. Microemulsions as novel drug carriers: the formation, stability, applications and toxicity 🔬⚗️
  4. Comparison of different water/oil microemulsions containing diclofenac sodium: preparation, characterization, release rate, and skin irritation studies 💧💊
  5. Extended release lipophilic indomethacin microspheres: formulation factors and mathematical equations fitted drug release rates 📊💉
  6. Modeling of theophylline release from different geometrical erodible tablets 🧬📖
  7. Efficacy of a new ketoconazole bioadhesive vaginal tablet on Candida albicans 🦠💊
  8. Permeation studies and histological examination of sheep nasal mucosa following administration of different nasal formulations with or without absorption enhancers 🐑👃
  9. Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4‐triazole containing hydrazide–hydrazones derived from (S)‐naproxen 💡🔬
  10. Preparation and evaluation of novel microemulsion-based hydrogels for dermal delivery of benzocaine 💧🧴

Conclusion:

Prof. Dr. H. Yeşim Karasulu is an exemplary candidate for the Excellence in Research award due to her consistent and impactful contributions to pharmaceutical research. Her work has led to significant advancements in drug delivery systems, evidenced by her substantial publication record, patents, and collaborations. Her achievements place her at the forefront of pharmaceutical technology and innovation, making her well-deserving of this recognition.

 

 

 

 

Yuan Ma | Cell Death Pathway | Best Researcher Award

Posted on by sciencefather

Prof Yuan Ma | Cell Death Pathway | Best Researcher Award

Prof Yuan Ma , Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University , China

Yuan Ma is a prominent Professor in the Department of Respiratory and Critical Care Medicine at The First Affiliated Hospital of Nanjing Medical University, China. With a medical background and a focus on bronchial asthma, Dr. Ma has made significant contributions to understanding the mechanisms of airway inflammation and remodeling. Through extensive research, he aims to identify novel molecular targets for asthma therapies. His work has been recognized internationally, underscoring his dedication to advancing clinical applications in respiratory medicine.

Publication Profile

Scopus

Strengths for the Award

  1. Extensive Research Experience: Yuan Ma has a robust academic background as a Professor in Respiratory and Critical Care Medicine. His focus on airway inflammation and remodeling in asthma is critical, given the increasing prevalence of respiratory diseases.
  2. Publication Record: With 25 articles in domestic journals and 13 in international journals, his publication record demonstrates both local and global recognition of his work. Notable articles in high-impact journals underscore the significance and relevance of his research.
  3. Innovative Contributions: Ma’s identification of necroptosis-related targets in asthma and the discovery of potential therapeutic compounds indicate significant advancements in the understanding and treatment of asthma, contributing to both academic knowledge and clinical practice.
  4. Grant Funding: Successfully presiding over projects funded by the National Natural Science Foundation of China highlights his ability to secure funding for impactful research, a crucial aspect of a successful research career.
  5. Patents: The issuance of 13 patents illustrates his innovative capacity and the potential for practical applications of his research findings.

Areas for Improvement

  1. Broader Collaborations: While Ma has made significant contributions, fostering collaborations with researchers from diverse fields could enhance interdisciplinary insights and expand the impact of his work.
  2. Professional Memberships: Engaging in professional organizations could provide networking opportunities and enhance visibility in the research community, further strengthening his position.
  3. Public Outreach: Increasing public engagement and dissemination of research findings could elevate awareness about asthma and his innovations, potentially leading to broader societal impact.

Education 

Dr. Yuan Ma obtained his medical degree from a prestigious institution, followed by specialized training in respiratory medicine. He completed his PhD with a focus on airway diseases, where he gained insights into the cellular and molecular mechanisms underlying asthma. Throughout his academic journey, Dr. Ma has cultivated a robust foundation in both clinical practice and research methodology, allowing him to bridge the gap between laboratory findings and patient care. His continuous pursuit of knowledge in respiratory health has led him to engage in various professional development opportunities, enhancing his expertise and contributing to his role as a leader in his field.

Experience 

Dr. Yuan Ma has extensive experience in both clinical and research settings, spanning over a decade. He has presided over significant research projects funded by the National Natural Science Foundation of China, exploring the pathogenesis of asthma and potential therapeutic interventions. His impressive track record includes 25 publications in national journals and 13 in international peer-reviewed journals, showcasing his commitment to advancing respiratory medicine. As a professor, he mentors medical students and residents, fostering the next generation of researchers and clinicians. His collaborative work with national and international peers has enriched his research, contributing to innovative approaches in asthma treatment. Additionally, his contributions to patent development demonstrate his drive to translate research findings into practical applications for better patient outcomes.

Research Focus 

Dr. Yuan Ma’s research primarily focuses on the mechanisms of airway inflammation and remodeling in bronchial asthma. He investigates necroptosis-related biomarkers and their regulatory mechanisms, aiming to identify novel therapeutic targets. His work encompasses exploring molecular compounds that can effectively modulate these targets, enhancing asthma diagnosis and treatment options. Dr. Ma’s innovative studies delve into the role of oxidative stress and MAPK signaling pathways in airway smooth muscle cell behavior. By examining the intricate interactions within the airway microenvironment, he seeks to uncover underlying processes that contribute to asthma exacerbations. His research has significant implications for developing targeted therapies, addressing the unmet needs of asthma patients, and ultimately improving clinical outcomes in respiratory medicine.

Publications Top Notes

  1. Screening, identification and targeted intervention of necroptotic biomarkers of asthma. 📄
  2. Caffeic acid phenethyl ester alleviates asthma by regulating the airway microenvironment via the ROS-responsive MAPK/Akt pathway. 🌱
  3. Morin Attenuates Ovalbumin-induced Airway Inflammation by Modulating Oxidative Stress-responsive MAPK Signaling. 🩺
  4. A case of male primary pulmonary choriocarcinoma. 🦠
  5. Implication of dendritic cells in lung diseases: immunological role of Toll-like receptor 4. 🔬
  6. Glomus tumors of the trachea: 2 case reports and a review of the literature. 📚
  7. Diosmetin prevents TGF-β1-induced epithelial-mesenchymal transition via ROS/MAPK signaling pathways. 🧬
  8. SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients. 🦠
  9. Characteristics of H7N9 avian influenza pneumonia: a retrospective analysis of 17 cases. 📊
  10. Galangin attenuates airway remodeling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthma. 🌿
  11. Melatonin modulates airway smooth muscle cell phenotype by targeting the STAT3/Akt/GSK-3β pathway in experimental asthma. 🌙
  12. Single-agent Maintenance Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-analysis. 🧑‍⚕️
  13. Effect of diosmetin on airway remodeling in a murine model of chronic asthma. 🐭

Conclusion

Yuan Ma’s exceptional research contributions in understanding and treating asthma position him as a strong candidate for the Best Researcher Award. His extensive publication record, innovative findings, and successful grant applications reflect a commitment to advancing respiratory medicine. Addressing areas for improvement could further enhance his profile and influence in the field. Overall, Ma’s achievements warrant recognition, and he is well-suited for this prestigious award.